An Open-Label, Randomized, Active Controlled Trial Evaluating Sublingual Dexmedetomidine for Moderate to Severe Agitation in Inpatients With Schizophrenia or Bipolar Disorder.

Faden, Justin; Veigne, Sandra; Yu, Daohai; Citrome, Leslie

doi:10.1097/JCP.0000000000002232

An Open-Label, Randomized, Active Controlled Trial Evaluating Sublingual Dexmedetomidine for Moderate to Severe Agitation in Inpatients With Schizophrenia or Bipolar Disorder.

2026-08-10, Journal of clinical psychopharmacology (10.1097/JCP.0000000000002232) (online)
Justin Faden, Sandra Veigne, Daohai Yu, and Leslie Citrome (?)

Agitation can occur in patients with schizophrenia, schizoaffective disorder, and bipolar disorder. This study evaluated the efficacy of sublingual dexmedetomidine, a selective alpha-2 adrenergic receptor agonist, for the treatment of acute agitation in "real-world" psychiatric inpatients.

This article has not yet been included in any curations.

Comments

There are no comments on this article yet.

You need to login or register to comment.

BioSothis

An Open-Label, Randomized, Active Controlled Trial Evaluating Sublingual Dexmedetomidine for Moderate to Severe Agitation in Inpatients With Schizophrenia or Bipolar Disorder.